A group of researchers have unraveled a new strategy to alter glucagon receptor signaling in the liver by changing its intracellular trafficking. Glucagon is a peptide hormone, that is responsible for glucose balance and thus the regulation of blood glucose levels. The novel approach offers therapeutic potential for the treatment of type 2 diabetes by uncoupling glucagon’s glucose and lipid metabolism-related effects.
During fasting, the hormone glucagon circulates through the body to initiate the release and breakdown of stored glucose and lipids from the liver to provide energy. Whether and how the usage of the two energy sources (glucose and lipids) can be activated independently was not known to date. A study has now identified that depleting the protein Vps37a from the liver alters the localization of the glucagon receptor within the cell, thereby allowing distinct activation of glucose metabolism on intracellular membranes without affecting lipids.
The liver is the main organ required for maintaining balanced blood glucose levels during fasting by releasing stored glucose upon external signals, such as glucagon. In type 2 diabetes, however, this pathway becomes overactivated, leading to glucose production from the liver despite already high blood glucose levels. This condition of too high glucose levels in the blood is called hyperglycemia. Pharmacological inhibition of glucagon action in the liver has been proven to be challenging, as glucagon is not only regulating glucose production but also mediating liver lipid breakdown. Therefore, blocking glucagon action bears lipid accumulation in the liver as negative side effect.
The team of researchers has now found a possible way to disconnect the two pathways, by interfering with the intracellular location and signaling pathways of glucagon receptor, thereby reviving glucagon antagonism as potential treatment for type 2 diabetes.
Obesity and associated type 2 diabetes prevalences are strongly increasing. However, as not every patient is responding equally well to already existing therapies, more treatment options are required. The study expands the current treatment horizon by offering an elegant way to make use of effective blood glucose reduction through glucagon inhibition without lipid-related side effects.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00412-0
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fvps37a-regulates&filter=22
Glucagon receptor localization regulates its metabolic signaling in the liver
- 1,203 views
- Added
Edited
Latest News
In-vitro 3D culture of func…
By newseditor
Posted 15 Jun
Neural balance in the brain…
By newseditor
Posted 15 Jun
Antimalarial compounds reli…
By newseditor
Posted 15 Jun
3D imaging of whole human b…
By newseditor
Posted 14 Jun
Reading pleasure and pain f…
By newseditor
Posted 14 Jun
Other Top Stories
Excessive nerves linked to severe asthma
Read more
More daytime sleepiness, more Alzheimer's disease?
Read more
Bravery cells found in the hippocampus
Read more
Diseased heart muscle cells have abnormally shortened telomeres
Read more
How olive oil and sleep could stave off heart attacks and strokes
Read more
Protocols
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
A co-culture system of macr…
By newseditor
Posted 10 Jun
Analysis of 3D pathology sa…
By newseditor
Posted 08 Jun
Long-term expandable mouse…
By newseditor
Posted 07 Jun
Publications
NRG1-ErbB4 signaling in the…
By newseditor
Posted 15 Jun
HPV integration and cervica…
By newseditor
Posted 15 Jun
Cerebral tau pathology in c…
By newseditor
Posted 15 Jun
Cerebral tau pathology in c…
By newseditor
Posted 15 Jun
Synthetic biodegradable mic…
By newseditor
Posted 15 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar